세계 손발바닥 농포증 치료 시장 – 2023-2030

Global Palmoplantar Pustulosis Treatment Market - 2023-2030

상품코드PH7364
발행기관DataM Intelligence
발행일2023.11.01
페이지 수187 Pages
포맷PDF + EXCEL
커버리지Global

₩6,525,000 – ₩11,775,000

보고서 요약(국문)

개요
전 세계 손발바닥 농포증 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
손발바닥 건선은 손과 발에 발생하는 건선의 일종입니다. 비늘처럼 벗겨지고 변색된 피부 병변이 특징입니다. 증상은 손과 발의 등쪽과 발바닥뿐만 아니라 손가락과 발가락 사이사이에도 나타날 수 있습니다. 손발바닥 농포증은 자가면역성 피부 질환이지만 정확한 원인은 아직 완전히 밝혀지지 않았습니다. 가족력이 있는 경우가 있으며, 성인이 되기 전에 발생하는 경우는 드뭅니다. 흡연자는 특히 이 유형의 건선에 걸리기 쉬운 것으로 알려져 있습니다.
건선은 완치할 수 없지만, 증상 관리에 도움이 되는 치료법은 있습니다. 국소 스테로이드와 같은 약물은 물집을 줄이기 위해 직접 도포하고, 살리실산 연고 및 요소 크림과 같은 연화제는 피부 보습에 가장 일반적으로 사용되며, 레티노이드 제제와 광선 요법도 사용됩니다. 심한 경우에는 메토트렉세이트 또는 사이클로스포린과 같은 면역억제제가 흔히 사용됩니다. 이러한 약물에 내약성이 없거나 효과가 없는 경우, 에타너셉트 및 아달리무맙과 같은 TNF-알파 차단제, 우스테키누맙과 같은 항IL-12/23 억제제, 주로 구셀쿠맙과 같은 항IL-23 억제제 및 항IL-17과 같은 생물학적 제제가 처방됩니다.
시장 동향: 성장 동력
신약 및 첨단 치료제에 대한 수요 증가
신약 및 첨단 치료제에 대한 수요 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 새로운 치료제는 손발바닥 농포증 증상 관리에 있어 충족되지 않은 요구를 해결하고, 더 나은 질병 관리를 위한 대안 또는 보완적인 치료 옵션을 제공하는 것을 목표로 합니다. 많은 제약 회사들이 향상된 치료 효과를 기대할 수 있는 새로운 치료제 개발에 집중하고 있습니다.
예를 들어, 2023년 8월 23일, 교와 키린(Kyowa Kirin Co., Ltd.)은 기존 치료법에 반응이 불충분한 손발바닥 농포증 치료를 위해 루미세프(LUMICEF, 브로달루맙)의 승인 적응증을 부분적으로 변경하는 것에 대해 후생노동성(MHLW)의 승인을 받았다고 발표했습니다.
루미세프는 IL-17A, IL-17A/F, IL-17F 및 IL-17C와 같은 염증성 사이토카인의 생물학적 활성을 IL-17A 수용체에 선택적으로 결합하여 억제하는 완전 인간 항-인터루킨-17(IL-17) 수용체 A 항체입니다. 루미세프(LUMICEF)는 손발바닥 농포증 치료제로 승인된 최초의 IL-17 경로 억제제입니다.
또한, FDA 승인과 같은 규제 기관의 승인은 환자들이 혁신적인 신약 개발에 대한 신뢰를 높이는 데 기여하고 있습니다. 예를 들어, 2021년 12월 15일, 베링거인겔하임(Boehringer Ingelheim)은 미국 식품의약국(FDA)이 전신 농포성 건선 악화 치료를 위한 스페솔리맙(spesolimab)의 생물학적 제제 허가 신청(BLA)을 접수하고 우선 심사(Priority Review)를 승인했다고 발표했습니다.
더 나아가, 손발바닥 농포증의 유병률 증가, 혁신적인 약물에 대한 FDA 승인 증가, 임상 시험 증가, 인식 제고, 새로운 치료법 개발의 진전, 광선 치료 기술의 발전 등이 향후 시장 성장을 견인할 것으로 예상됩니다.

제약 요인
국소 스테로이드 및 기타 약물과 관련된 합병증 및 부작용, 광선 치료의 높은 비용, 광선 치료와 관련된 위험, 그리고 더 나은 신속한 치료법의 부족과 같은 요인들이 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 손발바닥 농포증 치료 시장은 치료 유형, 투여 경로, 판매 채널 및 지역별로 세분화됩니다.
국소 스테로이드 부문은 손발바닥 농포증 치료 시장 점유율의 약 52.4%를 차지했습니다.
국소 스테로이드 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 일반적으로 이 질환은 완치할 수 없지만, 국소 스테로이드는 손발바닥 농포증 관리를 위한 1차 치료제로 간주됩니다. 국소 코르티코스테로이드라고도 하는 이 약물은 염증을 줄이고 발적, 가려움증, 농포 형성과 같은 증상을 완화하기 위해 환부에 직접 도포합니다.

또한, 국소 스테로이드는 면역 반응을 억제하고 염증을 감소시키는 작용을 합니다. 염증이 농포 발생에 중요한 역할을 하는 손발바닥 농포증의 경우, 이러한 약물은 증상과 심각도를 관리하는 데 도움이 될 수 있습니다. 국소 스테로이드는 다양한 강도로 출시되며, 강도 선택은 질환의 심각도와 병변 부위에 따라 달라집니다. 급성 악화 시에는 고강도 스테로이드를 단기간 사용하는 것이 필요할 수 있으며, 저강도 스테로이드는 유지 요법에 주로 사용됩니다.
더욱이, 국소 스테로이드는 폭넓은 보급, 수용성, 그리고 간편한 사용법 덕분에 가장 큰 시장 점유율을 차지하고 있습니다. 경우에 따라 치료 효과를 높이고 질환을 종합적으로 관리하기 위해 다른 국소 제제나 전신 약물과 병용하여 사용할 수도 있습니다. 또한, 국소 스테로이드의 광범위한 사용은 수요 증가로 이어집니다.

지리적 분석
북미는 시장 점유율의 약 41.2%를 차지했습니다.
북미 지역은 주요 기업들의 강력한 입지와 활발한 연구 개발 활동에 힘입어 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 특히 미국을 중심으로 제약 회사와 의료 기기 회사 등 주요 기업들이 활발하게 활동하고 있습니다. 주요 기업들의 적극적인 임상 시험 참여는 새로운 치료제와 환자 치료 결과 개선을 위한 대안적 치료법의 개발로 이어지고 있습니다.
예를 들어, 2021년 3월 8일, 염증 및 면역항암 분야에 적용 가능한 새로운 면역 조절 메커니즘에 초점을 맞춘 혁신적인 항체 후보 물질을 개발하는 임상 단계 생명공학 기업인 아나프티스바이오(AnaptysBio, Inc.)는 중등도에서 중증의 손발바닥 농포증(PPP) 치료를 위한 이미돌리맙(imsidolimab)의 2상 임상 시험 주요 결과를 발표했습니다.
또한, 북미 지역에는 연구 개발에 적극적으로 참여하는 제약 회사들이 많아 새롭고 혁신적인 치료법을 더 쉽게 접할 수 있을 것으로 예상됩니다. 연구 활동이 증가함에 따라 치료제 개발이 더욱 정밀해지고, 부작용 및 합병증이 줄어들어 환자 치료 결과가 향상되고 있습니다.
경쟁 환경
손발바닥 농포증 치료제 시장의 주요 글로벌 업체로는 F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Kyowa Kirin Co., Ltd., Novartis AG, Amgen Inc., Janssen Biotech, Inc., AdvaCare Pharma, Palsons Derma Pvt Ltd 및 SiNi Pharma Pvt Ltd 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 손발바닥 농포증 치료제 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 전 세계 제약 산업, 특히 손발바닥 농포증 치료제 시장은 전례 없는 어려움에 직면했습니다. COVID-19 팬데믹과 관련 제한 조치에 대한 관심이 집중되면서 많은 임상 시험 및 연구 활동이 일시적으로 중단되었기 때문입니다. 또한 팬데믹은 전 세계적으로 이러한 치료제의 공급망을 교란시켰습니다.

시장 세분화
치료 유형별
• 국소 스테로이드 또는 칼시포트리엔 크림
• 연화제
o 살리실산 연고
o 요소 크림
o 발뒤꿈치 밤
o 기타
• 레티노이드 제제
o 아시트레틴
o 레티놀
o 벡사로텐
o 알리트레티노인
o 기타
• 면역억제제
o 메토트렉세이트
o 사이클로스포린
o 기타
• 생물학적 제제
o TNF-알파 차단제
 에타너셉트
 아달리무맙
 기타
o 항 인터루킨 억제제
 우스테키누맙
 구셀쿠맙
 기타
• 테트라사이클린계 항생제
• 광선 치료
o 협대역 UVB
o 광화학 요법
o PUVA
• 기타
투여 경로별
• 경구
• 국소
• 정맥 주사
• 기타
매출액별 유통 채널
• 유통 채널
o 병원 약국
o 소매 약국
o 온라인 약국
• 최종 사용자
o 병원
o 피부과 클리닉
o 광선 치료 센터
o 학술 및 연구 기관
o 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 치료 유형, 투여 경로, 판매 채널 및 지역별 글로벌 손발바닥 농포증 치료 시장 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해
• 모든 세그먼트를 포함한 손발바닥 농포증 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트 • PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성되어 있습니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 손발바닥 농포증 치료 시장 보고서는 약 61개의 표, 61개의 그림, 그리고 187페이지 분량으로 구성됩니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global palmoplantar pustulosis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Palmoplantar psoriasis is a type of psoriasis on the hands and feet. It causes patches of scaly, flaky, discolored skin. Symptoms can affect the skin on the top and bottom of the hands and feet, as well as on and in between the fingers and toes. Palmoplantar pustulosis is an auto-inflammatory skin disease but the exact cause of the condition is still not fully understood. It sometimes runs in families and rarely occurs before adulthood. Smokers seem to be especially prone to this type of psoriasis.
Moreover, there isn’t a cure for psoriasis, but treatment is available to help manage the symptoms. Medications such as topical steroids are applied directly to reduce the blisters, emollients such as salicylic acid ointment and urea cream are most commonly used to moisturize the skin, retinoid medications, and phototherapy are also used, and in severe cases, immunosuppressants like methotrexate or cyclosporine are commonly used. If these medications are not tolerated or are inefficient, biologicals like TNF-alpha blockers such as etanercept and adalimumab, anti-IL-12/23 inhibitors such as ustekinumab, anti-IL-23 inhibitors mainly guselkumab and anti-IL-17 are prescribed.
Market Dynamics: Drivers
Increasing demand for novel and advanced therapeutics
The increasing demand for novel and advanced therapeutics is expected to drive the market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the management of symptoms of palmoplantar pustulosis by providing alternative or complementary treatment options for better disease management. Many pharmaceutical companies are focusing on the development of novel therapeutics with advanced outcomes.
For instance, on August 23, 2023, Kyowa Kirin Co., Ltd. released that the company has received approval from the Ministry of Health, Labour and Welfare (MHLW) for partial change of approved indication of LUMICEF (brodalumab) for the treatment of palmoplantar pustulosis that respond inadequately to existing therapies.
LUMICEF is a fully human anti-interleukin-17 (IL-17) receptor A antibody that inhibits the biological activity of inflammatory cytokines such as IL-17A, IL-17A/F, IL-17F and IL-17C by binding to IL-17A receptor selectively. LUMICEF is the first IL-17 pathway inhibitor approved for palmoplantar pustulosis.
In Addition, regulatory approvals such as FDA approvals increase the trust in patients about the development of novel advanced therapeutics. For instance, on December 15, 2021, Boehringer Ingelheim cleared that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for spesolimab for the treatment of generalized pustular psoriasis flares.
Further, the increasing prevalence of palmoplantar pustulosis, rising FDA approvals for innovative drugs, increasing clinical trials, increasing awareness and advancements in the development of novel therapies and technological advancements in phototherapy are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications and side effects associated with topical steroids and other drugs, the high cost of the phototherapy treatment, risks associated with phototherapy and lack of better and quick treatment are expected to hamper the market.
Segment Analysis
The global palmoplantar pustulosis treatment market is segmented based on treatment type, route of administration, sales channel and region.
The topical steroids segment accounted for approximately 52.4% of the palmoplantar pustulosis treatment market share
The topical steroids segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for this disease, but topical steroids are considered first-line therapeutics for the management of palmoplantar pustulosis. These medications, also known as topical corticosteroids, are applied directly to the affected skin to help reduce inflammation and alleviate symptoms such as redness, itching, and the formation of pustules.
Moreover, topical steroids work by suppressing the immune response and reducing inflammation. In palmoplantar pustulosis, where inflammation plays a significant role in the development of pustules, these medications can help manage symptoms and severity. Topical steroids come in varying strengths, and the choice of strength depends on the severity of the condition and the affected areas. Short-term use of high-potency steroids may be necessary for acute flare-ups, while lower-potency options are often used for maintenance therapy.
Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. In some cases, topical steroids may be used in combination with other topical agents or systemic medications to enhance therapeutic effects and manage the condition comprehensively. In addition, their wide adoption also increases the demand for the topical steroids.
Geographical Analysis
North America accounted for approximately 41.2% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing R&D activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for better patient outcomes.
For instance, on March 08, 2021, AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, released that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe palmoplantar pustulosis (PPP).
Furthermore, the region has a strong presence of pharmaceutical companies engaged in research and development. New and innovative treatments may be more readily available in North America. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.
Competitive Landscape
The major global players in the palmoplantar pustulosis treatment market include F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Kyowa Kirin Co., Ltd., Novartis AG, Amgen Inc., Janssen Biotech, Inc., AdvaCare Pharma, Palsons Derma Pvt Ltd and SiNi Pharma Pvt Ltd. among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global palmoplantar pustulosis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global palmoplantar pustulosis treatment market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications globally.
Market Segmentation
By Treatment Type
• Topical Steroids or Calcipotriene Creams
• Emollients
o Salicylic Acid Ointment
o Urea Cream
o Heel Balm
o Others
• Retinoid Medications
o Acitretin
o Retinol
o Bexarotene
o Alitretinoin
o Others
• Immunosuppressants
o Methotrexate
o Cyclosporine
o Others
• Biologics
o TNF-Alpha Blockers
 Etanercept
 Adalimumab
 Others
o Anti Interleukin Inhibitors
 Ustekinumab
 Guselkumab
 Others
• Tetracycline Antibiotics
• Phototherapy
o Narrowband UVB
o Photochemotherapy
o PUVA
• Others
By Route Of Administration
• Oral
• Topical
• Intravenous
• Others
By Sales Channel
• Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• End-User
o Hospitals
o Dermatology Clinics
o Phototherapy Centers
o Academic and Research Institutes
o Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global palmoplantar pustulosis treatment market segmentation based on treatment type, route of administration, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of palmoplantar pustulosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global palmoplantar pustulosis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Novel and Advanced Therapeutics
4.1.2. Restraints
4.1.2.1. Complications Associated with the Use of Topical Steroids
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. Volume Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Topical Steroids or Calcipotriene Creams*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Emollients
7.3.1. Salicylic Acid Ointment
7.3.2. Urea Cream
7.3.3. Heel Balm
7.3.4. Others
7.4. Retinoid Medications
7.4.1. Acitretin
7.4.2. Retinol
7.4.3. Bexarotene
7.4.4. Alitretinoin
7.4.5. Others
7.5. Immunosuppressants
7.5.1. Methotrexate
7.5.2. Cyclosporine
7.5.3. Others
7.6. Biologics
7.6.1. TNF-Alpha Blockers
7.6.1.1. Etanercept
7.6.1.2. Adalimumab
7.6.1.3. Others
7.6.2. Anti Interleukin Inhibitors
7.6.2.1. Ustekinumab
7.6.2.2. Guselkumab
7.6.2.3. Others
7.7. Tetracycline Antibiotics
7.8. Phototherapy
7.8.1. Narrowband UVB
7.8.2. Photochemotherapy
7.8.3. PUVA
7.9. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Intravenous
8.5. Others
9. By Sales Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.1.2. Market Attractiveness Index, By Sales Channel
9.2. Distribution Channel*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Hospital Pharmacies
9.2.4. Retail Pharmacies
9.2.5. Online Pharmacies
9.3. End-User
9.3.1. Hospitals
9.3.2. Dermatology Clinics
9.3.3. Phototherapy Centers
9.3.4. Academic and Research Institutes
9.3.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Teva Pharmaceuticals USA, Inc.
12.3. Pfizer Inc.
12.4. Kyowa Kirin Co., Ltd.
12.5. Novartis AG
12.6. Amgen Inc.
12.7. Janssen Biotech, Inc.
12.8. AdvaCare Pharma
12.9. Palsons Derma Pvt Ltd
12.10. SiNi Pharma Pvt Ltd
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

F. Hoffmann-La Roche Ltd., 4. Key Developments, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Kyowa Kirin Co., Ltd., Novartis AG, Amgen Inc., Janssen Biotech, Inc., AdvaCare Pharma, Palsons Derma Pvt Ltd, SiNi Pharma Pvt Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Palmoplantar Pustulosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 7 Global Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 11 Global Palmoplantar Pustulosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Palmoplantar Pustulosis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 14 North America Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 16 North America Palmoplantar Pustulosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 18 South America Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 South America Palmoplantar Pustulosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 22 Europe Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 24 Europe Palmoplantar Pustulosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Palmoplantar Pustulosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Palmoplantar Pustulosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Palmoplantar Pustulosis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Palmoplantar Pustulosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 32 F. Hoffmann-La Roche Ltd: Overview

Table 33 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 34 F. Hoffmann-La Roche Ltd: Key Developments

Table 35 Teva Pharmaceuticals USA, Inc.: Overview

Table 36 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 37 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 38 Pfizer Inc.: Overview

Table 39 Pfizer Inc.: Product Portfolio

Table 40 Pfizer Inc.: Key Developments

Table 41 Kyowa Kirin Co., Ltd.: Overview

Table 42 Kyowa Kirin Co., Ltd.: Product Portfolio

Table 43 Kyowa Kirin Co., Ltd.: Key Developments

Table 44 Novartis AG: Overview

Table 45 Novartis AG: Product Portfolio

Table 46 Novartis AG: Key Developments

Table 47 Amgen Inc.: Overview

Table 48 Amgen Inc.: Product Portfolio

Table 49 Amgen Inc.: Key Developments

Table 50 Janssen Biotech, Inc.: Overview

Table 51 Janssen Biotech, Inc.: Product Portfolio

Table 52 Janssen Biotech, Inc.: Key Developments

Table 53 AdvaCare Pharma: Overview

Table 54 AdvaCare Pharma: Product Portfolio

Table 55 AdvaCare Pharma: Key Developments

Table 56 Palsons Derma Pvt Ltd: Overview

Table 57 Palsons Derma Pvt Ltd: Product Portfolio

Table 58 Palsons Derma Pvt Ltd: Key Developments

Table 59 SiNi Pharma Pvt Ltd: Overview

Table 60 SiNi Pharma Pvt Ltd: Product Portfolio

Table 61 SiNi Pharma Pvt Ltd: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Palmoplantar Pustulosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 3 Global Palmoplantar Pustulosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Palmoplantar Pustulosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 5 Global Palmoplantar Pustulosis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Palmoplantar Pustulosis Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 7 Topical Steroids or Calcipotriene Creams Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Emollients Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Retinoid Medications Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Immunosuppressants Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Biologics Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Tetracycline Antibiotics Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Phototherapy Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Others Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Global Palmoplantar Pustulosis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 16 Oral Route of Administration in Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Topical Route of Administration in Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Intravenous Route of Administration in Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Others Route of Administration in Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Palmoplantar Pustulosis Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 21 Distribution Channel Sales Channel in Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 End-User Sales Channel in Global Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Global Palmoplantar Pustulosis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Asia-Pacific Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Europe Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 South America Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 Middle East and Africa Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 North America Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 North America Palmoplantar Pustulosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 31 North America Palmoplantar Pustulosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 32 North America Palmoplantar Pustulosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 33 North America Palmoplantar Pustulosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 35 South America Palmoplantar Pustulosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 36 South America Palmoplantar Pustulosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 37 South America Palmoplantar Pustulosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 38 South America Palmoplantar Pustulosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 39 Europe Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 40 Europe Palmoplantar Pustulosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 41 Europe Palmoplantar Pustulosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 Europe Palmoplantar Pustulosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 43 Europe Palmoplantar Pustulosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 45 Asia-Pacific Palmoplantar Pustulosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 46 Asia-Pacific Palmoplantar Pustulosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 47 Asia-Pacific Palmoplantar Pustulosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 48 Asia-Pacific Palmoplantar Pustulosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 49 Middle East & Africa Palmoplantar Pustulosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 50 Middle East & Africa Palmoplantar Pustulosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 51 Middle East & Africa Palmoplantar Pustulosis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 52 Middle East & Africa Palmoplantar Pustulosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 53 F. Hoffmann-La Roche Ltd: Financials

Figure 54 Teva Pharmaceuticals USA, Inc.: Financials

Figure 55 Pfizer Inc.: Financials

Figure 56 Kyowa Kirin Co., Ltd.: Financials

Figure 57 Novartis AG: Financials

Figure 58 Amgen Inc.: Financials

Figure 59 Janssen Biotech, Inc.: Financials

Figure 60 AdvaCare Pharma: Financials

Figure 61 Palsons Derma Pvt Ltd: Financials

Figure 62 SiNi Pharma Pvt Ltd: Financials